Ouma John H, King Charles H, Muchiri Eric M, Mungai Peter, Koech Davy K, Ireri Edmund, Magak Philip, Kadzo Hilda
Biomedical Science and Technology Programme, Maseno University, Maseno, Kenya.
Am J Trop Med Hyg. 2005 Aug;73(2):359-64.
Late benefits of remote antischistosomal therapy were estimated among long-term residents of an area with high transmission of Schistosoma haematobium (Msambweni, Kenya) by comparing infection and disease prevalence in two local adult cohorts. We compared 132 formerly treated adults (given treatment in childhood or adolescence > or = 10 years previously) compared with 132 age- and sex-matched adults from the same villages who had not received prior treatment. The prevalence of current infection, hematuria, and ultrasound bladder abnormalities were significantly lower among the previously treated group, who were found to be free of severe bladder disease. Nevertheless, heavy infection was equally prevalent (2-3%) in both study groups, and present rates of hydronephrosis were not significantly different. Therapy given in childhood or adolescence appears to improve risk for some but not all manifestations of S. haematobium infection in later adult life. Future prospective studies of continued treatment into adulthood will better define means to obtain optimal, community-based control of S. haematobium-related disease in high-risk locations.
通过比较两个当地成年队列中的感染率和疾病患病率，对曼氏血吸虫（肯尼亚姆桑布韦尼）高传播地区的长期居民进行了远程抗血吸虫治疗的晚期效益评估。我们将132名曾接受过治疗的成年人（在儿童期或青少年期接受治疗，时间超过或等于10年前）与来自相同村庄的132名年龄和性别匹配、未接受过先前治疗的成年人进行了比较。在先前接受治疗的组中，当前感染、血尿和膀胱超声异常的患病率显著较低，且发现该组没有严重的膀胱疾病。然而，重度感染在两个研究组中的患病率相同（2%-3%），肾盂积水的现患率也没有显著差异。儿童期或青少年期接受的治疗似乎可改善成年后期曼氏血吸虫感染某些而非所有表现的风险。未来对成年期持续治疗的前瞻性研究将更好地确定在高危地区实现基于社区的曼氏血吸虫相关疾病最佳控制的方法。
